3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Recurrence
2
Waldenstrom Macroglobulinemia
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia, Hairy Cell
1
Burkitt Lymphoma
1
Interventions
Rituximab
24
Cyclophosphamide
10
fludarabine phosphate
8
Bortezomib
7
Lenalidomide
6
Tacrolimus
5
Mycophenolic Acid
5
idelalisib
4
ibrutinib
4
Peripheral Blood Stem Cell Transplantation
4
Antilymphocyte Serum
4
tanespimycin
3
Whole-Body Irradiation
3
Radiotherapy
3
Indium
3
Dasatinib
3
Cyclosporine
3
pomalidomide
2
ofatumumab
2
nelarabine
2
ibritumomab tiuxetan
2
Vincristine
2
Sirolimus
2
Radiation
2
Prednisone
2
Polymerase Chain Reaction
2
Methotrexate
2
Melphalan
2
Magnetic Resonance Spectroscopy
2
Ipilimumab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Waldenstrom Macroglobulinemia
×
brexucabtagene autoleucel
×
Clear all
NCT05537766
2026-03-10
ZUMA-25
Gilead Sciences
Phase 2
Terminated
19 enrolled
28 charts